Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines

Journal of Infectious Diseases

Volumn 207, Issue 5, 2013, Pages 700-708

  Sun, Wellington ^a,e   Eckels, Kenneth H ^a,f   Putnak, J Robert ^a,g   Lyons, Arthur G ^a   Thomas, Stephen J ^a,g   Vaughn, David W ^a,c,i   Gibbons, Robert V ^a,g   Fernandez, Stefan ^a,d   Gunther, Vicky J ^a,g   Mammen, Mammen P ^a,d   Statler, John D ^b,h,k   Innis, Bruce L ^c,j  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (United States)

^d ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^e CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^f Pilot Bioproduction Facility   (United States)

^g Department of Immunology   (United States)

^h UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

ⁱ Global Clinical Research and Development   (United States)

^j Vaccine Discovery and Development   (United States)

^k Pulmonary Associates of Fredericksburg   (United States)

more..

Author keywords

dengue; live virus challenge; tetravalent vaccine

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DENGUE VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; TETRAVALENT DENGUE VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; ASCITES; BLEEDING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; EXPERIMENTAL DENGUE VIRUS CHALLENGE; EXPERIMENTAL STUDY; FEMALE; GALLBLADDER DISEASE; GALLBLADDER FIBROSIS; HEMOCONCENTRATION; HUMAN; HUMAN EXPERIMENT; HYPERTRANSAMINASEMIA; HYPOTENSION; IMMUNE FUNCTION TEST; IMMUNOPROPHYLAXIS; INJECTION SITE ERYTHEMA; MACULOPAPULAR RASH; MALE; NEUTROPENIA; NORMAL HUMAN; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; REVACCINATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; THROMBOCYTOPENIA;

EID: 84873620717     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis744     Document Type: Article

References (41)

1. Franco C, Hynes NA, Bouri N, Henderson DA. The dengue threat to the United States. Biosecur Bioterror 2010; 8:273-6
2. Farrar J, Focks D, Gubler D, et al. The WHO/TDR Dengue Scientific Working Group. Towards a global dengue research agenda. Trop Med Intl Health 2007; 12:695-9
3. World Health Organization. Dengue and dengue hemorrhagic fever. http://www.who.int/mediacentre/factsheets/fs117/en/index.html. Accessed 16 May 2010
4. Halstead SB. Pathogenesis of dengue: Challenges to molecular biology. Science 1988; 239:476-81
5. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: Disease regulation by immune complexes. Lancet Infect Dis 2010; 10:712-22
6. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine [published correction appears in Lancet Infect Dis 2010; 10:304]. Lancet Infect Dis 2009; 9:678-87
7. Hombach J. Vaccines against dengue: A review of current candidate vaccines at advanced development stages. Rev Panam Salud Publica 2007; 21:254-60
8. Sabin AB. Dengue. In: Viral and rickettsial infections of man. 3rd ed. Philadelphia: J. B. Lippincott, 1959:361
9. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immuol 2008; 21:123-32
10. Halstead SB, Rojanasuphot S, Sangkawibha N. Original antigenic sin in dengue. Am J Trop Hyg 1983; 32:154-6
11. Hombach J. Guidelines for clinical trials of dengue vaccine in endemic areas. J Clin Virol 2009; S2:S7-9
12. Eckels KH, Dubois DR, Putnak R, et al. Modification of dengue virus strains by passage in primary dog kidney cells: Preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 2003; 69(SUPPL6):12-6
13. Sun W, Nisalak A, Gettayacamin M, et al. Protection of rhesus monkeys against dengue virus challenge following tetravalent live-Attenuated dengue virus vaccination. J Infect Dis 2006; 193:1658-65
14. Koraka P, Benton S, van Amerongen G, Stittelaar KJ, Osterhaus ADME. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naive and previously infected cynomolgus macaques. Vaccine 2007; 25:5409-16
15. Sun W, Edelman R, Kanesa-Thasan N, et al. Vaccination of human volunteers with monovalent and tetravalent live-Attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003; 69(SUPPL6):24-31
16. Edelman RE, Wasserman SS, Bodison SA, et al. Phase 1 trial of 16 formulations of a tetravalent live-Attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69(SUPPL6):48-60
17. Simasathien S, Thomas SJ, Watanaveeradej V, et al. Safety and immunogenicity of a tetravalent live-Attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 2008; 78:426-33
18. Sun W, Cunningham D, Wasserman SS, et al. Phase 2 clinical trial of three formulations of tetravalent live-Attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccine 2009; 5:33-40
19. Edelman R, Tacket CO, Wasserman SS, et al. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis 1994; 170:1448-55
20. McKee KT, et al. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg 1987; 36:435-42
21. Kotloff KL. Human challenge studies with infectious agents. J Investig Med 2003; 51(SUPPL1):S6-11
22. Gunther VJ, Putnak JR, Eckels KH, et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 2011; 29:3895-904
23. Innis BL, Eckels KH, Kraiselburd E, et al. Virulence of a live dengue virus vaccine candidate: A possible marker of dengue virus attenuation. J Infect Dis 1988; 158:876-80
24. Mammen MP, Lyons A, Innis BL, et al. Low-passaged dengue virus strains evaluated as potential human challenge strains (submitted
25. Yuill TM, Sukhavachana P, Nisalak A, Russell PK. Dengue-virus recovery by direct and delayed plaques in LLC-MK2 cells. Am J Trop Med Hyg 1968; 17:441-8
26. Sadon N, Delers A, Jarman RG, et al. A new quantitative RT-PCR method for sensitive detection of dengue virus in serum samples. J Virol Methods 2008; 153:1-6
27. Putnak JR, de la Barrera R, Burgess T, et al. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg 2008; 79:115-22
28. Dengue haemorrhagic fever: Diagnosis, treatment, prevention and control. 2nd ed. Geneva: World Health Organization, 1997:13
29. Raviprakash K, Wang D, Ewing D, et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 2008; 82:6927-34
30. Guy B, Barban V, Mantel N, et al. Evolution of interference between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009; 80:302-11
31. Kanesa-Thasan N, Sun W, Kim-Ahn G, et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001; 19:3179-88
32. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010; 201:370-7
33. Capeding RZ, Luna IA, Bomasang E, et al. Live-Attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines. Vaccine 2011; 29:3863-72
34. Watanaveeradej V, Simasathien S, Nisalak A, et al. Safety and immunogenicity of a tetravalent live-Attenuated dengue vaccine in flavivirusnaive infants. Am J Trop Med Hyg 2011; 85:341-51
35. Statler J, Mammen M, Lyons A, Sun W. Sonographic findings of healthy volunteers infected with dengue virus. J Clin Ultrasound 2008; 36:413-7
36. Wahid SF, Sanusi S, Zawawi MM, Ali RA. A comparison of the pattern of liver involvement in dengue hemorrhagic fever with classic dengue fever. Southeast Asian J Trop Med Public Health 2000; 31:259-63
37. Kuo CH, Tai DI, Chang-Chien CS, Lan CK, Chiou SS, Liaw YF. Liver biochemical tests and dengue fever. AM J Trop Med Hyg 1992; 47:265-70
38. Parkash O, Almas A, Jafri SM, Hamid S, Akhtar J, Alishah H. Severity of acute hepatitis and its outcome in patients with dengue fever in a tertiary care hospital Karachi, Pakistan (South Asia). BMC Gastroenterol 2010; 10:43
39. Bihn PT, Matheus S, Huong VT, Deparis X, Marechal V. Early clinical and biological features of severe clinical manifestations of dengue in Vietnamese adults. J Clin Virol 2009; 45:276-80
40. Epidemiology, burden of disease and transmission. In: Dengue, guidelines for diagnosis, treatment, prevention and control. New ed. Geneva: World Health Organization, 2009:11
41. Durbin AP, Schimidt A, Elwood D, et al. Heterotypic dengue infection with live attenuated monovalent dengue virus vaccines: Implications for vaccinations of populations in areas where dengue is endemic. J Infect Dis 2011; 203:327-34